Table.

Clinical and demographic characteristics of study subjects.

	Non-COVID	COVID-19		Convalescents	P value
		Mild/moderate	Severe/critical
Study subjects, n	54	52	74	66
Age in years, mean ± SEM	48 ± 1.9	52 ± 2.8	67.0 ± 1.7	52.4 ± 2.2	<.0001
Sex
Men, n	29	28	46	35	.5349h
Women, n	25	24	28	31
Clinical data
Survival rate, %		100%	74%
BMI	27.2 ± 0.6	27.2 ± 0.6c	31.1 ± 1.0e	29.8 ± 2.1g	.0196
Peak D-dimer, ng/mL, mean ± SEM		1118 ± 223d	3007 ± 352f		.0002
Peak CRPa, mg/dL, mean ± SEM		8.3 ± 1.1	19.5 ± 1.3		<.0001
Peak WBCsb, 103/uL, mean ± SEM		8.3 ± 0.5	13.2 ± 0.9		<.0001
Peak platelet count, 103/uL, mean ± SEM		291 ± 22	322 ± 19		.2094
Comorbidities, n (%)
Non-COVID inflammatory disease		11 (20.8%)	21 (28.4%)	2 (4.1%)	.4086i
Autoimmune disease	1	2 (3.8%)	1 (1.4%)	1 (2%)	.5706i
Diabetes	2	8 (15.1%)	23 (31.1%)	6 (12.2%)	.0584i
Cancer (active and history)		2 (3.8%)	6 (8.1%)	1 (2%)	.4671i
Thrombosis	1	4 (7.5%)	3 (4.1%)	0 (0%)	.4499i
Kidney failure	NA	1 (1.9%)	14 (18.9%)	1 (2%)	.0039i
Hypertension	NA	14 (26.4%)	40 (54.1%)	6 (12.2%)	.0021i
Lung disease	NA	2 (3.8%)	10 (13.5%)	2 (4.1%)	.0734i
Heart disease	NA	7 (13.2%)	17 (23%)	2 (4.1%)	.2501i
GI tract disease	NA	3 (5.7%)	6 (8.1%)	2 (4.1%)	.7338i
Blood type, n (%)
A	17 (32%)	23 (44%)	35 (47%)	23 (35%)	.0415j
B	13 (24%)	17 (33%)	11 (15%)	20 (30%)
O	18 (33%)	9 (17%)	15 (20%)	17 (26%)
AB	6 (11%)	3 (6%)	13 (18%)	6 (9%)

%, Percentage subjects in the same cohort; NA, data were not available.

Data were not available for some study subjects.

^aC-reactive protein.

^bWhite blood cells.

^c3.

^d19 NA, 1 > 5000.

^e15.

^f9 NA, 4 > 5000.

^g17.

^hFisher’s exact test was used to evaluate the differences in sex distribution between non-COVID, mild/moderate, and severe/critical.

ⁱFisher’s exact tests were used to evaluate differences between mild/moderate and severe/critical.

^jFisher’s exact tests were used to evaluate the differences in blood type distribution between non-COVID, mild/moderate, and severe/critical.